Akman Tulay, Oztop Ilhan, Unek Ilkay Tugba, Koca Dogan, Unal Olcun Umit, Salman Tarık, Yavuzsen Tugba, Yilmaz Ahmet Ugur, Somali Isıl, Demir Necla, Ellidokuz Hulya
Division of Medical Oncology, Tepecik Education and Research Hospital, Izmir, Turkey.
Chemotherapy. 2014;60(4):228-38. doi: 10.1159/000371838. Epub 2015 Apr 10.
Surgical excision constitutes an important part of the treatment of local advanced malignant melanoma. Due to the high recurrence risk, adjuvant high-dose interferon therapy is still the only therapy used in stage IIB and III high-risk melanoma patients.
One hundred two high-risk malignant melanoma patients who received high-dose interferon-α-2b therapy were evaluated retrospectively. The clinicopathological features, survival times, and prognostic factors of the patients were determined.
The median disease-free and overall survival times were 25.2 and 60.8 months, respectively. Our findings revealed that male gender, advanced disease stage, lymph node involvement, lymphatic invasion, the presence of ulceration, and a high Clark level were significant negative prognostic factors.
In light of the favorable survival results obtained in this study, high-dose interferon treatment as adjuvant therapy for high-risk melanoma is still an efficient treatment and its possible side effects can be prevented by taking the necessary precautions.
手术切除是局部晚期恶性黑色素瘤治疗的重要组成部分。由于复发风险高，辅助性高剂量干扰素治疗仍是IIB期和III期高危黑色素瘤患者唯一使用的治疗方法。
回顾性评估了102例接受高剂量α-2b干扰素治疗的高危恶性黑色素瘤患者。确定了患者的临床病理特征、生存时间和预后因素。
无病生存期和总生存期的中位数分别为25.2个月和60.8个月。我们的研究结果显示，男性、疾病晚期、淋巴结受累、淋巴管浸润、溃疡的存在以及高Clark分级是显著的阴性预后因素。
鉴于本研究获得的良好生存结果，高剂量干扰素治疗作为高危黑色素瘤的辅助治疗仍然是一种有效的治疗方法，并且通过采取必要的预防措施可以预防其可能的副作用。
